Takeda Pharmaceutical Co Ltd (TKPYY.PK)
* Result boosted by one-off payments from Bayer and Takeda
TOKYO - The European Commission has approved the sale of Takeda Pharmaceutical Co Ltd's Entyvio drug to treat patients with ulcerative colitis and Crohn's disease, Japan's biggest drugmaker said on Wednesday.
TOKYO, May 28 - The European Commission has approved the sale of Takeda Pharmaceutical Co Ltd's Entyvio drug to treat patients with ulcerative colitis and Crohn's disease, Japan's biggest drugmaker said on Wednesday.
May 20 - U.S. health regulators on Tuesday approved a drug from Japan's Takeda Pharmaceutical Co Ltd to treat the chronic debilitating inflammatory diseases ulcerative colitis and Crohn's disease.
TOKYO, May 16 - Takeda Pharmaceutical Co Ltd , Japan's biggest drug company, has no interest in acquisitions driven by tax benefits or synergies, its chief financial officer said, dismissing the forces behind Pfizer Inc's $106 billion offer for AstraZeneca PLC.
* Nintendo tumbles to lowest since June 2013 * Toyota, Takeda to report earnings later in the day * Chinese trade data eyed By Ayai Tomisawa TOKYO, May 8 - Japan's Nikkei share average rose on Thursday, recovering from a three-week low hit the previous day after comments by the U.S. Federal Reserve chief helped investor sentiment, but Nintendo slid after posting a wider-than-expected loss. Nintendo Co fell 5.6 percent to 10,070 yen, its lowest since June 2013, afte
For the full text of this story please click the following link:
SAN FRANCISCO/TOKYO - Takeda Pharmaceutical Co Ltd said it would contest $6 billion in punitive damages imposed by a jury in the United States in a case that accused Japan's largest drugmaker of concealing cancer risks associated with its Actos diabetes drug.
* Louisiana jury orders $6 bln damages from Takeda, $3 bln from Eli Lilly
SAN FRANCISCO/TOKYO - Takeda Pharmaceutical Co Ltd said it would contest $6 billion in punitive damages imposed by a U.S. federal jury in a case alleging that Japan's largest drugmaker had concealed cancer risks associated with its Actos diabetes drug.
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Takeda Pharmaceutical Co Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: MarketLine (a Datamonitor Company)
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.